MAP3K7 and neurodegenerative disease: TAK1 is an endogenous inhibitor of RIPK1, and an age-dependent reduction in TAK1 expression might be a key factor that contributes to neurodegenerative disease models, such as frontotemporal dementia and amyotrophic lateral sclerosis [18].